您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报 (医学版) ›› 2022, Vol. 60 ›› Issue (6): 107-113.doi: 10.6040/j.issn.1671-7554.0.2021.1237

• • 上一篇    

长效针剂在三省部分社区精神分裂症患者中的应用现状及存在问题

李佳博1,2,欧阳江峰3,杨丁1,2,高京1,2,孙强1,2   

  • 发布日期:2022-06-17
  • 通讯作者: 孙强. E-mail:qiangs@sdu.edu.cn

Long-acting injectable application in patients with schizophrenia in communities of three provinces: current status and problems

LI Jiabo1,2, OUYANG Jiangfeng3, YANG Ding1,2, GAO Jing1,2, SUN Qiang1,2   

  1. 1. Center for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China;
    2. NHC Key Lab of Health Economics and Policy Research (Shandong University), Jinan 250012, Shandong, China;
    3. Zhucheng Center for Disease Control and Prevention, Zhucheng 262200, Shandong, China
  • Published:2022-06-17

摘要: 目的 分析长效针剂在三省部分社区精神分裂症患者中的应用现状及存在问题,为促进其应用推广提供参考。 方法 采用目的抽样法,依据最大差异化原则选取云浮、成都、临沂三地,通过对长效针剂应用中各利益相关者访谈获取资料,以政策为补充,运用主题框架法分析,采用非参数检验比较地区间共同关注问题频数差异。 结果 三地在长效针剂接受程度、注射资质、支持政策等方面相似,在长效针剂应用范围、纳入标准、注射地点、资金保障、参与部门上存在差异;长效针剂在社区精神分裂症患者应用中存在认知及治疗观念局限、患者治疗可及性不足、资金保障可持续性面临挑战、部门参与及协作较少等问题。 结论 长效针剂在三省部分社区精神分裂症患者中的应用现状方面既有共性又有差异。针对存在的问题,应加强宣传、沟通并尽早为患者提供长效针剂,因地制宜实施更为合理注射方案,降低针剂价格并合理制定落实医保政策,充分发挥政府相关部门组织协调作用。

关键词: 长效针剂, 社区, 精神分裂症, 对比研究

Abstract: Objective To analyze the current status and problems of long-acting injectable(LAI)application in patients with schizophrenia in communities of three provinces, so as to provide reference for promoting its application and promotion. Methods Purpose sampling was used to select Yunfu, Chengdu and Linyi according to the principle of maximum differentiation. Data were obtained through interviews with various stakeholders.Thematic framework approach was adopted for analysis, and nonparametric test was used to compare the frequency differences of common concerns among the three sample areas. Results The three sample areas were comparable in the acceptance degree, injection qualification and support policies of LAI, but there were differences in the application scope, inclusion criteria, injection location, capital guarantee and participating departments.There were also problems in the application of LAI in patients with schizophrenia in communities, such as limitations in cognitive and treatment concept, insufficient access to treatment, insufficient funding sustainability, inadequate involvement and collaboration of departments, and so on. Conclusion The sample areas have both similarities and differences in the current status of LAI application in patients with schizophrenia in communities. For the existing problems, the following measures are necessary: strengthen publicity and communication; provide LAI for patients as soon as possible; implement a more reasonable injection scheme according to local conditions; reduce injection prices; formulate and implement reasonable medical insurance policies; give full play to the organization and coordination role of relevant government departments.

Key words: Long-acting injectable, Communities, Schizophrenia, Comparative study

中图分类号: 

  • R749.3
[1] 中华医学会精神医学分会精神分裂症协作组. 抗精神病药长效针剂治疗精神分裂症的专家共识[J]. 中华精神科杂志, 2020(2): 99-100. Chinese Schizophrenia Coordination Group. Expert consensus on long-acting injectable in the treatment of schizophrenia[J]. Chinese Journal of Psychiatry, 2020(2): 99-100.
[2] 李喆, 杨亚黎, 吴胜利, 等. 严重精神障碍患者社区规范管理模式及实施效果研究[J]. 中国全科医学, 2018, 21(35): 4322-4327. LI Zhe, YANG Yali, WU Shengli, et al. Effect of community-based standardized mental disorders management onpatients with severe mental disorders[J]. Chinese General Practice, 2018, 21(35): 4322-4327.
[3] 赵靖平. 中国精神分裂症防治指南[M]. 2版. 北京:中华医学电子音像出版社, 2015:1-2.
[4] 中华医学会精神医学分会精神分裂症协作组. 抗精神病药长效针剂在精神分裂症治疗中的作用[J]. 中华精神科杂志, 2020(3):163-170. Chinese Schizophrenia Coordination Group. Long-acting injectable in the treatment of schizophrenia[J]. Chinese Journal of Psychiatry, 2020(3):163-170.
[5] 舒良, 王刚. 棕榈酸帕利哌酮注射液个案报告概述[J]. 中国心理卫生杂志, 2012, 26(B06): 42. SHU Liang, WANG Gang. Summary of case report of paliperidone palmitate injection[J]. Chinese Mental Health Journal, 2012, 26(B06): 42.
[6] Jari T, Ellenor MR, Maila M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia [J]. JAMA Psychiatry, 2017, 74(7): 686-693.
[7] 人力资源社会保障部. 关于印发国家基本医疗保险、工伤保险和生育保险药品目录(2017年版)的通知(人社部发〔2017〕15号)[EB/OL].(2017-02-21)[2021-07-09]. http://www.mohrss.gov.cn/wap/zc/zcwj/201702/t20170223_266775.html.
[8] 中华人民共和国国家卫生健康委员会. 严重精神障碍管理治疗工作规范(2018年版)[J]. 中国实用乡村医生杂志, 2018, 25(7): 11-22. National Health Commission of the peoples Republic of China. Norms for the management and treatment of severe mental disorders(2018 Edition)[J]. Chinese Practical Journal of Rural Doctor, 2018, 25(7): 11-22.
[9] 唐伟, 杨馥银, 温娜, 等. 棕榈酸帕利哌酮长效针剂与利培酮治疗首次发病精神分裂症患者的随机对照研究[J]. 中华精神科杂志, 2016, 49(2): 76-80. TANG Wei, YANG Fuyin, WEN Na, et al. A comparative study of paliperidone palmitate injections and risperidone on long-term effects and prognosis for the first-episode schizophrenic patients[J]. Chinese Journal of Psychiatry, 2016, 49(2): 76-80.
[10] 陈礼贤, 翁小娟, 徐丹红, 等. 长效针剂对轻中度精神分裂症患者的临床治疗效果[J]. 中国医师杂志, 2020, 22(4): 592-595. CHEN Lixian, WENG Xiaojuan, XU Danhong, et al. Clinical therapeutic effect of long-acting injection on patients with mild to moderate schizophrenia[J]. Journal of Chinese Physician, 2020, 22(4): 592-595.
[11] 胡晓松, 赵燕, 吴尊友. 云南省文山州HIV感染者抗病毒治疗脱失影响因素的定性研究[J]. 中华疾病控制杂志, 2018, 22(8): 822-825. HU Xiaosong, ZHAO Yan, WU Zunyou. Qualitative study of factors associated with antiretroviral therapy drop-out among HIV-infected patients in Wenshan prefecture, Yunnan Province[J]. Chinese Journal of Disease Control & Prevention, 2018, 22(8): 822-825.
[12] 汪涛, 陈静, 胡代玉, 等. 运用主题框架法进行定性资料分析[J]. 中国卫生资源, 2006,9(2): 86-88. WANG Tao, CHEN Jing, HU Daiyu, et al. Thematic framework method was used for qualitative data analysis[J]. Chinese Health Resources, 2006, 9(2): 86-88.
[13] 新华社. 国家卫生计生委等部门发布合理用药十大核心信息[EB/OL].(2013-12-10)[2021-10-04]. http://www.gov.cn/jrzg/2013-12/10/content_2545748.htm.
[14] 宓为峰, 马文斌, 熊健, 等. 精神分裂症患者用药依从性及复发情况的调查[J]. 中华精神科杂志, 2012, 45(1): 25-28. MI Weifeng, MA Wenbin, XIONG Jian, et al. Compliance with antipsychotic treatment and relapse in schizophrenia[J]. Chinese Journal of Psychiatry, 2012, 45(1): 25-28.
[15] 黄悦勤. 中国精神卫生调查概况[J]. 心理与健康, 2018(10): 14-16. HUANG Yueqin. Survey of mental health in China[J]. Psychology & Health, 2018(10): 14-16.
[16] Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies[J]. World Psychiatry, 2013, 12(3): 216-226.
[17] Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition [J]. Am J Psychiatry, 2004, 161(2 Suppl): 1-56.
[18] Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects [J]. World J Biol Psychiatry, 2013, 14(1): 2-44.
[19] Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology [J]. J Psychopharmacol, 2011, 25(5): 567-620.
[20] Remington G, Addington D, Honer W, et al. Guidelines for the Pharmacotherapy of Schizophrenia in Adults [J]. Can J Psychiatry, 2017, 62(9): 604-616.
[21] Weiden PJ, Kim E, Bermak J, et al. Does Half-life matter after antipsychotic discontinuation? a relapse comparison in schizophrenia with 3 different formulations of paliperidone [J]. J Clin Psychiatry, 2017, 78(7): e813-e820.
[22] Magnusson MO, Samtani MN, Plan EL, et al. Dosing and switching strategies for paliperidone palmitate 3-month formulation in patients with schizophrenia based on population pharmacokinetic modeling andsimulation, and clinical trial data [J]. CNS Drugs, 2017, 31(4): 273-288.
[23] Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia [J]. Schizophr Res, 2015, 169(1-3): 393-399.
[24] Munday J, Greene M, Chang E, et al. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data [J]. Curr Med Res Opin, 2019, 35(7): 1231-1239.
[25] Kane JM, Schooler NR, Marcy P, et al. Patients with early-phase schizophrenia will accept treatment with sustained-release medication(long-acting injectable antipsychotics): results from therecruitment phase of the PRELAPSE trial [J]. J Clin Psychiatry, 2019, 80(3): 18m12546. doi: 10.4088/JCP.18m12546.
[26] Chiou CF, Wang BC, Caldwell R, et al. The cost reduction in hospitalization associated with paliperidone palmitate in the Peoples Republic of China, Korea, and Malaysia [J]. Neuropsychiatr Dis Treat, 2015, 11(6): 1989-1994.
[27] Baser O, Xie L, Pesa J, et al. Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics [J]. J Med Econ, 2015, 18(5): 357-365.
[28] Druais S, Doutriaux A, Cognet M, et al. Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in france [J]. Pharmacoeconomics, 2016, 34(4): 363-391.
[29] Lefebvre P, Muser E, Joshi K, et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on health care resource use and costs in veterans with schizophrenia and comorbid substance abuse [J]. Clin Ther, 2017, 39(7): 1380-1395.
[30] 周宇, 傅启伟, 黄牡婵. 棕榈酸帕利哌酮长效针剂治疗精神疾病双相障碍近远期效果分析[J]. 中国药事, 2018, 32(6): 799-803. ZHOU Yu, FU Qiwei, HUANG Muchan. Short-term and long-termeffects of paliperidonepalmitatelong-actinginjection in treating mental illness in bipolar disorder[J]. Chinese Pharmaceutical Affairs, 2018, 32(6): 799-803.
[1] 王辛,郭丹,梁佳瑞,郭丽,王健. 社会资本对老年人健康促进行为的影响[J]. 山东大学学报 (医学版), 2021, 59(7): 97-103.
[2] 吕岩,于潇,蔺新英,赵琦,王保珍. 聊城市老年女性膳食模式与抑郁症状的关系[J]. 山东大学学报 (医学版), 2020, 58(11): 103-108.
[3] 张振堂,杨洋,韩福俊,陈向华,季晓康,王永超,王淑康,孙苑潆,李敏,陈亚飞,王丽,薛付忠,刘言训. 基于社区2型糖尿病患者的心脑血管事件5年风险预测模型[J]. 山东大学学报(医学版), 2017, 55(6): 108-113.
[4] 蔺晨, 郭芳, 季维娜, 于文成. 社区获得性肺炎患者的外周血TNF-α、sTREM-1、α1-APG水平[J]. 山东大学学报(医学版), 2015, 53(2): 61-64.
[5] 刘盈君, 张涛, 王璐, 刘佳, 常学润, 张敬悬, 薛付忠. 基于随机森林的精神分裂症血清代谢组学研究[J]. 山东大学学报(医学版), 2015, 53(2): 92-96.
[6] 龚晴, 张昊, 乔颖. 精神分裂症患者家属生活质量调查分析[J]. 山东大学学报(医学版), 2014, 52(Z2): 177-178.
[7] 王玉琴, 哈秀英, 徐卫国. 三种抗精神分裂症药物的疗效和经济学评价[J]. 山东大学学报(医学版), 2014, 52(Z2): 196-197.
[8] 刘倩倩, 肖宏, 尹爱田, 孙晓杰. 济南市社区卫生服务人员心理健康状况及相关因素分析[J]. 山东大学学报(医学版), 2014, 52(9): 104-108.
[9] 赵燕1,王刚1,陈大方2,程宇航1,陈雪彦1 . 首发未治精神分裂症患者IL-6、IL-10和IL-12水平及影响因素[J]. 山东大学学报(医学版), 2014, 52(4): 70-73.
[10] 雷震,江虹,尹世平,丁娟,潘芳. 积极心理干预对社区老年人心理健康与幸福感水平的影响[J]. 山东大学学报(医学版), 2014, 52(2): 93-96.
[11] 李阳, 曹枫林, 钟耕坤, 林萍珍, 梁鑫浩. 精神分裂症患者青少年亲属生态学执行功能特征及其与侵害的关系[J]. 山东大学学报(医学版), 2014, 52(11): 86-91.
[12] 杨丽敏1,2,王妍1,孙萌萌2,崔开艳2,王丽娜2,刘兰芬1,2. 首发精神分裂症患者的信息处理速度及其影响因素[J]. 山东大学学报(医学版), 2013, 51(9): 100-104.
[13] 王妍1,杨丽敏1,2,孙萌萌2,崔开艳2,杨晓东2,乔冬冬1,2,王汝展2,张敬悬2,刘兰芬1,2. 儿童期虐待与精神分裂症患者人格特征的相关性[J]. 山东大学学报(医学版), 2013, 51(8): 103-106.
[14] 贾堂宏1,侯廷成1,谢忠元1,窦克宏1,张济2,边学峰2,时延申3,牛纪伦4,杨华5. 济南市社区人群代谢综合征检出率及危险因素调查[J]. 山东大学学报(医学版), 2013, 51(7): 100-106.
[15] 师晓林1,康殿民2,黄鹏翔2,廖玫珍2, 陶小润2,王国永2,苏生利2,王振宏3. 山东某市社区新型毒品吸食者梅毒感染状况及其影响因素分析[J]. 山东大学学报(医学版), 2013, 51(12): 107-110.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!